Thank You!

Thank You!

We will keep you updated

In the meantime, follow us on our social media and see other Median contents that may interest you

  • The latest from Median

    [Podcast] The Competitive Advantages Of AI-powered Clinical Trial Imaging to Advance Human Health
    The association aims to develop and implement smart imaging biomarkers to better understand the mechanism of action (MOA) of oncology drugs and collect more evidence of efficiency in early phase clinical trials.
    Both Imaging Lab and eyonis™ teams had a poster presentation on December 2nd at the 2023 North America Conference on Lung Cancer (NACLC) in Chicago. Read more details on our press release.
    Median Technologies is among the first 50 companies to be chosen to join the French government’s ETIncelles program. The ETIncelles program aims to transform 500 French high growth potential SMEs into market leading Intermediate-Sized Enterprises (ETI), by 2027.
    Median Technologies (ALMDT) unveils a new identity, including a new name, logo, tagline for its iBiopsy® AI/ML tech-based suite of software as medical devices (SaMD) and business unit, as part of an extensive rebranding initiative.
    Median will be exhibiting at the ECR, which will take place February 28 to March 3 in Vienna. We will be so pleased to see you in person at our booth #AI-17, Expo X1, AI-area.